Drugs / INDEGLITAZAR
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00447629 | Jan → Mar 2007 | diabetes mellitus | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00448032 | Nov 2006 → Mar 2007 | diabetes mellitus | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00425919 | Jan → Oct 2007 | type 2 diabetes mellitus | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INDEGLITAZAR | ChEMBL registry synonym — accepted as the source's own label CHEMBL1232583 ↗ |
| Known as | PPM-204 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00425919 ↗ |
| Modality | Small molecule | — CHEMBL1232583 ↗ |
| Route | Oral | “Single Oral Doses of PPM 204” NCT00447629 ↗ |